Natera: Trade the Oncology Momentum — A Measured Long with Defined Risk
Natera is trading near $200 with multiple oncology catalysts in motion: positive MRD data for Signatera, a strategic acquisition of Foresight Diagnostics, and growing market demand for esoteric and reproductive genetic tests. Fundamentals show improving free cash flow ($109.1M) and low leverage, but valuation is rich (P/S ~12, P/B ~16). This trade …